Arcellx, Inc. (ACLX)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Arcellx, Inc. (ACLX) trades at $115.07 with AI Score 45/100 (Grade C). Arcellx, Inc. is a clinical-stage biotechnology company focused on developing innovative immunotherapies for cancer and other incurable diseases. Market cap: $6.73B, Sector: Healthcare.
Price live · AI analysis from May 10, 2026ACLX stock analysis for 2026: Analysts have set a consensus price target of $111.42 for Arcellx, Inc., suggesting 3.2% downside from the current price of $115.07. The AI MoonshotScore is 45/100, indicating a neutral outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
ACLX: the 1 perspectives are evenly split.
How is this calculated? →Arcellx, Inc. (ACLX) Healthcare & Pipeline Overview
Arcellx, Inc. is a clinical-stage biotechnology firm specializing in immunotherapies for cancer and other incurable diseases. Their lead candidate, CART-ddBCMA, targets relapsed or refractory multiple myeloma, positioning them in the competitive CAR-T therapy market with a focus on innovative ddCAR technology.
What Is the Investment Thesis for ACLX?
Arcellx presents a notable research candidate within the biotechnology sector, driven by its innovative ddCAR technology and promising clinical trial results for CART-ddBCMA in treating relapsed or refractory multiple myeloma. The company's focus on enhancing CAR-T cell therapy efficacy and safety addresses a significant unmet need in oncology. Key value drivers include the successful completion of ongoing Phase 1 trials, advancement of its pipeline candidates (ACLX-001, ACLX-002, ACLX-003) into clinical development, and potential partnerships for commercialization. However, the company's negative profit margin of -1027.3% and gross margin of -64.8% highlight the risks associated with clinical-stage biotechnology companies, including regulatory hurdles, clinical trial failures, and competition from established players. The company's beta of 0.23 suggests lower volatility compared to the overall market.
Based on FMP financials and quantitative analysis
ACLX Key Highlights
- Arcellx's lead product candidate, CART-ddBCMA, is in Phase 1 clinical trials for relapsed or refractory multiple myeloma, demonstrating potential in a high-need market.
- The company's ddCAR technology aims to improve the efficacy and safety of CAR-T cell therapies, addressing limitations of existing treatments.
- Arcellx is developing a pipeline of additional immunotherapeutic candidates targeting AML/MDS and solid tumors, expanding its potential market reach.
- The company's market capitalization is $6.70 billion, reflecting investor confidence in its technology and pipeline.
- Arcellx's focus on cell-based therapies aligns with the growing trend towards personalized medicine in oncology.
Who Are ACLX's Competitors?
ACLX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ARWR Arrowhead Pharmaceuticals, Inc. | $86.85 | +3.41% | $12.23B | 31 |
| PCVX Vaxcyte, Inc. | $58.39 | +4.12% | $8.43B | 59 |
| PTGX Protagonist Therapeutics, Inc. | $130.90 | -0.55% | $8.42B | — |
| ALKS Alkermes plc | $54.65 | +0.13% | $9.11B | 51 |
| IMVT Immunovant, Inc. | $38.60 | -0.49% | $7.92B | 57 |
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ACLX's Key Strengths?
- Innovative ddCAR technology platform.
- Promising clinical trial results for CART-ddBCMA.
- Strong intellectual property position.
- Experienced management team.
What Are ACLX's Weaknesses?
- Clinical-stage company with no approved products.
- High R&D expenses and negative profit margin.
- Reliance on clinical trial success and regulatory approval.
- Competition from established pharmaceutical companies.
What Could Drive ACLX Stock Higher?
- Announcement of Phase 1 clinical trial results for CART-ddBCMA in relapsed or refractory multiple myeloma.
- Initiation of clinical trials for ACLX-001 in r/r MM.
- Advancement of ACLX-002 and ACLX-003 into clinical development for r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
- Potential for strategic partnerships or collaborations with larger pharmaceutical companies.
What Are the Key Risks for ACLX?
- Negative return on equity (-55.4%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Insider selling — insiders were net sellers of roughly $185.6M recently.
- Clinical trial failures or delays.
- Regulatory hurdles and delays in obtaining marketing approval.
- Competition from other cell therapy companies.
- Adverse events associated with its therapies.
- High R&D expenses and need for additional funding.
What Are the Growth Opportunities for ACLX?
- Expansion into Earlier Lines of Therapy: Arcellx has the opportunity to expand the use of CART-ddBCMA into earlier lines of therapy for multiple myeloma. Currently, it is being evaluated for relapsed or refractory patients. Success in earlier lines could significantly broaden the addressable patient population. The multiple myeloma market is projected to reach $37.5 billion by 2030, offering substantial revenue potential. This expansion is contingent on positive clinical trial results and regulatory approval.
- Development of Allogeneic Cell Therapies: Arcellx can leverage its expertise in cell therapy to develop allogeneic (off-the-shelf) CAR-T cell therapies. Allogeneic therapies offer advantages over autologous therapies, including reduced manufacturing time and cost, and broader patient accessibility. The allogeneic CAR-T market is expected to grow rapidly, driven by these advantages. Arcellx's success in this area would depend on overcoming challenges related to graft-versus-host disease and immune rejection.
- Targeting Solid Tumors: Arcellx has the opportunity to expand its pipeline to include immunotherapies targeting solid tumors. Solid tumors represent a much larger market than hematological malignancies, but are also more challenging to treat with cell therapies. Arcellx's ddCAR technology could potentially be adapted to address the unique challenges of solid tumors, such as tumor heterogeneity and immunosuppressive microenvironments. Success in this area would require significant R&D investment and clinical trial innovation.
- Strategic Partnerships and Collaborations: Arcellx can pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its product candidates. Partnerships can provide access to funding, expertise, and infrastructure, as well as expand Arcellx's market reach. The biotechnology industry is characterized by frequent collaborations between smaller biotech firms and larger pharmaceutical companies. Arcellx's attractive technology platform and promising clinical data make it a potential partner for companies seeking to expand their presence in the cell therapy market.
- Expansion into New Geographic Markets: Arcellx can expand its geographic reach beyond the United States and Europe. Emerging markets, such as China and India, represent significant growth opportunities for cell therapies. These markets have large patient populations and increasing healthcare spending. However, expansion into new geographic markets would require navigating complex regulatory landscapes and establishing local partnerships. Arcellx's success in these markets would depend on its ability to adapt its products and strategies to local conditions.
What Opportunities Does ACLX Have?
- Expansion into earlier lines of therapy for multiple myeloma.
- Development of allogeneic CAR-T cell therapies.
- Targeting solid tumors with its immunotherapies.
- Strategic partnerships and collaborations.
What Threats Does ACLX Face?
- Clinical trial failures.
- Regulatory hurdles and delays.
- Competition from other cell therapy companies.
- Adverse events associated with its therapies.
What Are ACLX's Competitive Advantages?
- Proprietary ddCAR technology platform that enhances CAR-T cell therapies.
- Strong intellectual property portfolio protecting its technologies and product candidates.
- Clinical trial data demonstrating the potential efficacy and safety of its therapies.
- Experienced management team with expertise in cell therapy development.
- Focus on addressing unmet medical needs in oncology.
What Does ACLX Do?
Arcellx, Inc., founded in 2014 and headquartered in Redwood City, California, is a biotechnology company dedicated to developing innovative immunotherapies for patients suffering from cancer and other currently incurable diseases. Originally incorporated as Encarta Therapeutics, Inc., the company rebranded as Arcellx, Inc. in January 2016 to reflect its evolving focus on cell-based therapies. Arcellx's core technology revolves around its D-Domain Co-receptor Technology (ddCAR), which aims to enhance the efficacy and safety of CAR-T cell therapies. Their lead product candidate, CART-ddBCMA, is currently undergoing Phase 1 clinical trials as a treatment for patients with relapsed or refractory multiple myeloma (r/r MM). In addition to CART-ddBCMA, Arcellx is developing a pipeline of other immunotherapeutic candidates, including ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA for r/r MM. ACLX-002 and ACLX-003 are being developed for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), along with other AML/MDS product candidates and solid tumor programs. The company's strategic focus is on addressing unmet medical needs in oncology through the development of next-generation cell therapies.
What Products and Services Does ACLX Offer?
- Develops immunotherapies for cancer and other incurable diseases.
- Focuses on D-Domain Co-receptor Technology (ddCAR) to enhance CAR-T cell therapies.
- Conducts clinical trials to evaluate the safety and efficacy of its product candidates.
- Develops CART-ddBCMA for the treatment of relapsed or refractory multiple myeloma.
- Creates ACLX-001, an immunotherapeutic combination for treating r/r MM.
- Develops ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
- Explores solid tumor programs.
How Does ACLX Make Money?
- Develops and patents novel immunotherapies.
- Conducts preclinical and clinical research to validate its technologies.
- Seeks regulatory approval for its product candidates.
- Potentially commercializes its products directly or through partnerships.
- Generates revenue through product sales, licensing agreements, and research collaborations.
What Industry Does ACLX Operate In?
Arcellx operates within the rapidly evolving biotechnology industry, specifically in the field of cell and gene therapy. The CAR-T cell therapy market is experiencing significant growth, driven by the increasing prevalence of cancer and the limitations of traditional treatments. The competitive landscape includes established pharmaceutical companies and emerging biotech firms developing CAR-T therapies and other immunotherapies. Arcellx's ddCAR technology aims to differentiate itself by improving the efficacy and safety of CAR-T cells, addressing key challenges such as cytokine release syndrome and off-target effects. The biotechnology sector is characterized by high R&D costs, regulatory hurdles, and intense competition, but also offers significant potential for innovation and market disruption.
Who Are ACLX's Key Customers?
- Patients with cancer and other incurable diseases.
- Oncologists and hematologists who treat these patients.
- Hospitals and cancer centers that provide treatment.
- Pharmaceutical companies that may partner with Arcellx.
- Payers (insurance companies, government healthcare programs) that reimburse for treatment.
Company Profile
Arcellx, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Redwood City, US. The company is led by CEO Rami Elghandour. ACLX has traded publicly since 2022.
ROE -55%Key Financial Metrics
Return on equity for Arcellx, Inc. stands at -55.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -37.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -3.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 4.44 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -3.5%, the inverse of the P/E and a quick read on earnings relative to price.
ACLX Valuation & Market Position
With a $6.73B market cap, Arcellx, Inc. sits in the mid-cap segment of the market. Relative to its peer group, ACLX's quantitative score of 45/100 is roughly in line with the peer average of 50/100.
Quarterly Financial Performance: Arcellx, Inc.
Revenue for Arcellx, Inc. came in at $1.7M during Q4 2025, a 66.6% contraction versus the preceding quarter. The company recorded a net loss of $58.1M, with diluted EPS of $-1.00. Revenue has contracted over three consecutive quarters, which investors in this mid-cap Healthcare stock should monitor closely. Across the four most recent quarters, ACLX averaged $-1.01 in diluted EPS.
F-Score 1/9Financial Health
Arcellx, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 17.98 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project Arcellx, Inc. revenue of about $73.3M for fiscal 2026, with EPS near $-3.67. The estimate reflects 7 contributing analysts.
Net sellingInsider Activity
Over the past six months, Arcellx, Inc. insiders filed 30 SEC Form 4 transactions — 30 sales and 0 purchases. On net that is roughly 1.9M shares disposed (about $185.6M), a signal worth weighing alongside the fundamentals.
ACLX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying activity indicates confidence from executives about the company's future prospects.
- Positive community sentiment has emerged around Arcellx's innovative therapies, suggesting growing interest among retail investors.
- Analysts have highlighted the potential of Arcellx's pipeline, which could lead to significant market opportunities in the biotech sector.
- The company has been actively engaging with investors, fostering a sense of transparency and trust that could bolster its market position.
Bear Case
- Concerns about the competitive landscape in the biotech industry may be dampening investor enthusiasm for Arcellx.
- Recent social sentiment has shown some skepticism regarding the timelines for product approvals, which could impact future growth.
- Market perception has been affected by broader economic uncertainties, leading to cautious sentiment among traders.
- Some community discussions reflect worries about the company's cash runway, which could pose risks if funding is not secured timely.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · February 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $2M | -$58M | -$1.00 |
| Q3 2025 | $5M | -$56M | -$0.99 |
| Q2 2025 | $8M | -$53M | -$0.94 |
| Q1 2025 | $8M | -$62M | -$1.13 |
Based on FMP financials and quantitative analysis
ACLX Latest News
No recent news available for ACLX.
ACLX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ACLX.
Price Targets
Consensus target: $111.42
ACLX MoonshotScore
What does this score mean?
The MoonshotScore rates ACLX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Rami Elghandour
CEO
Rami Elghandour is the Chief Executive Officer of Arcellx, Inc. He has extensive experience in the biopharmaceutical industry, with a focus on oncology and cell therapy. Prior to joining Arcellx, he held leadership positions at several biotechnology companies, including Bristol-Myers Squibb and Celgene. He has a proven track record of building and leading successful teams, as well as driving the development and commercialization of innovative therapies. He is responsible for overseeing Arcellx's overall strategy and operations.
Track Record: Under Rami Elghandour's leadership, Arcellx has advanced its lead product candidate, CART-ddBCMA, into Phase 1 clinical trials and expanded its pipeline of immunotherapeutic candidates. He has also overseen the company's growth and development, including securing funding and building a strong team. His strategic decisions have positioned Arcellx as a leader in the field of cell therapy.
Common Questions About ACLX (Healthcare)
What does Arcellx, Inc. do?
Arcellx, Inc. is a clinical-stage biotechnology company focused on developing and commercializing innovative immunotherapies for patients with cancer and other incurable diseases. The company's core technology is its D-Domain Co-receptor Technology (ddCAR), which is designed to enhance the efficacy and safety of CAR-T cell therapies. Their lead product candidate, CART-ddBCMA, is currently in Phase 1 clinical trials for the treatment of relapsed or refractory multiple myeloma. Arcellx is also developing a pipeline of other immunotherapeutic candidates targeting AML/MDS and solid tumors.
What do analysts say about ACLX stock?
Analyst coverage of Arcellx, Inc. typically focuses on the potential of its ddCAR technology and the clinical progress of CART-ddBCMA. Key valuation metrics include the potential market size for multiple myeloma and other target indications, as well as the probability of success for its clinical trials. Growth considerations include the expansion of its pipeline, potential partnerships, and regulatory approvals. Analyst consensus is Unknown.
What are the main risks for ACLX?
The main risks for Arcellx, Inc. include the inherent uncertainties associated with clinical-stage biotechnology companies, such as clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. Specific risks include the potential for adverse events associated with its therapies, the need for additional funding to support its R&D efforts, and the potential for delays in obtaining marketing approval. The company's negative profit and gross margins highlight the financial risks associated with its current stage of development.
How does Arcellx, Inc. navigate regulatory approval processes?
Arcellx, Inc. navigates regulatory approval processes by working closely with regulatory agencies such as the FDA to ensure compliance with all applicable regulations and guidelines. This involves submitting detailed clinical trial data, manufacturing information, and safety data to support its applications for marketing approval. Arcellx also engages with regulatory agencies to address any questions or concerns that may arise during the review process. The company's regulatory strategy is focused on obtaining accelerated approval pathways, such as breakthrough therapy designation, to expedite the development and approval of its therapies.
What are the key growth opportunities for ACLX in healthcare?
Arcellx, Inc. has several key growth opportunities within the healthcare sector. These include expanding the use of CART-ddBCMA into earlier lines of therapy for multiple myeloma, developing allogeneic CAR-T cell therapies, and targeting solid tumors with its immunotherapies. The company also has the opportunity to pursue strategic partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its product candidates. These growth opportunities are driven by the increasing prevalence of cancer and the limitations of traditional treatments, as well as the growing demand for personalized medicine.
What are the key factors to evaluate for ACLX?
Arcellx, Inc. (ACLX) holds an AI score of 45/100 (low). Analysts target $111.42 (-3%). Not financial advice.
How frequently does ACLX data refresh on this page?
ACLX prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven ACLX's recent stock price performance?
Arcellx, Inc. (ACLX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative ddCAR technology platform. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Financial data is based on the most recent available information.
- Clinical trial outcomes are inherently uncertain.